Atorvastatin inhibits inflammatory hypernociception

British Journal of Pharmacology

Volumn 149, Issue 1, 2006, Pages 14-22

  Santodomingo Garzon T ^a   Cunha, T M ^a   Verri, W A ^a   Valerio D A R ^a   Parada, C A ^a   Poole, S ^b   Ferreira, S H ^a   Cunha, F Q ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Atorvastatin; Hyperalgesia; IL 1 ; Mevalonate; Nitric oxide; Pain

Indexed keywords

ANALGESIC AGENT; ANTIGEN; ATORVASTATIN; BRADYKININ; CHEMOKINE; CHOLESTEROL; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN E2; PROSTANOID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MALE; MEASUREMENT; MOUSE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SENSITIZATION; SKIN;

ANIMALS; BRADYKININ; CHOLESTEROL; CYTOKINES; DINOPROSTONE; ENZYME INHIBITORS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERALGESIA; INFLAMMATION; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; MALE; MICE; NITRIC OXIDE SYNTHASE; PAIN MEASUREMENT; PYRROLES; SKIN;

EID: 33748053317     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706836     Document Type: Article

References (73)

1. Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T et al. (2003). Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 197: 725-733.
2. Ali S, Mann DA (2004). Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochem Funct 22: 67-79.
3. Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA (2001). Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 32: 980-986.
4. Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V et al. (2005). Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 516: 282-289.
5. Bhatnagar D (1998). Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther 79: 205-230.
6. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J (2003). Antiinflammatory and immunomodulatory effects of statins. Kidney Int 63: 12-23.
7. Brackertz D, Mitchell GF, Mackay IR (1977). Antigen-induced arthritis in mice. I. Induction of arthritis in various strains of mice. Arthritis Rheum 20: 841-850.
8. Bustos C, Hernandez-Presa MA, Ortego M, Tunon J, Ortega L, Perez F et al. (1998). HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32: 2057-2064.
9. Chen H, Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K (2000). Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 36: 923-928.
10. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R (1995). Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 76: 21A-28A.
11. Coutaux A, Adam F, Willer JC, Le Bars D (2005). Hyperalgesia and allodynia: peripheral mechanisms. Joint Bone Spine 72: 359-371.
12. Cunha FQ, Ferreira SH (1986). The release of a neutrophil chemotactic factor from peritoneal macrophages by endotoxin: inhibition by glucocorticoids. Eur J Pharmacol 129: 65-76.
13. Cunha FQ, Ferreira SH (2003). Peripheral hyperalgesic cytokines. Adv Exp Med Biol 521: 22-39.
14. Cunha FQ, Lorenzetti BB, Poole S, Ferreira SH (1991). Interleukin-8 as a mediator of sympathetic pain. Br J Pharmacol 104: 765-767.
15. Cunha FQ, Poole S, Lorenzetti BB, Ferreira SH (1992). The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. Br J Pharmacol 107: 660-664.
16. Cunha TM, Verri Jr WA, Silva JS, Poole S, Cunha FQ, Ferreira SH (2005). A cascade of cytokines mediates mechanical inflammatory hypernociception in mice. Proc Natl Acad Sci USA 102: 1755-1760.
17. Cunha TM, Verri Jr WA, Vivancos GG, Moreira IF, Reis S, Parada CA et al. (2004). An electronic pressure-meter nociception paw test for mice. Braz J Med Biol Res 37: 401-407.
18. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. (1998). Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615-1622.
19. Duarte ID, dos Santos IR, Lorenzetti BB, Ferreira SH (1992). Analgesia by direct antagonism of nociceptor sensitization involves the arginine-nitric oxide-cGMP pathway. Eur J Pharmacol 217: 225-227.
20. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA et al. (1998). Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95: 8880-8885.
21. Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, Rickli H et al. (2004). Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 175: 83-90.
22. Ferreira SH, Duarte ID, Lorenzetti BB (1991). The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur J Pharmacol 201: 121-122.
23. Ferreira SH, Lorenzetti BB, Bristow AF, Poole S (1988). Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334: 698-700.
24. Ferreira SH, Lorenzetti BB, Poole S (1993). Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. Br J Pharmacol 110: 1227-1231.
25. 2+ dependent process. Prostaglandins 18: 179-190.
26. Ferro D, Parrotto S, Basili S, Alessandri C, Violi F (2000). Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 36: 427-431.
27. Furberg CD, Adams Jr HP, Applegate WB, Byington RP, Espeland MA, Hartwell T et al. (1994). Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 90: 1679-1687.
28. Gomez-Hernandez A, Sanchez-Galan E, Martin-Ventura JL, Vidal C, Blanco-Colio LM, Ortego M et al. (2006). Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J Cardiovasc Pharmacol 47: 60-69.
29. Grundy SM (1988). HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 319: 24-33.
30. Hebert PR, Gaziano JM, Chan KS, Hennekens CH (1997). Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 278: 313-321.
31. Heerey A, Barry M, Ryan M, Kelly A (2000). The potential for drug interactions with statin therapy in Ireland. Ir J Med Sci 169: 176-179.
32. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C et al. (1998). Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101: 2711-2719.
33. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, Gomez-Hernandez A, Tunon J, Hernandez-Vargas P et al. (2002). Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis 160: 49-58.
34. Hilgendorff A, Muth H, Parviz B, Staubitz A, Haberbosch W, Tillmanns H et al. (2003). Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 41: 397-401.
35. Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K (2001). Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J Cardiovasc Pharmacol 38: 69-77.
36. Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S et al. (2000). Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci 67: 863-876.
37. Khasar SG, McCarter G, Levine JD (1999). Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors. J Neurophysiol 81: 1104-1112.
38. Koh KK (2000). Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47: 648-657.
39. Kwak B, Mulhaupt F, Myit S, Mach F (2000). Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402.
40. Laufs U (2003). Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 58: 719-731.
41. Laufs U, Liao JK (1998). Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271.
42. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H et al. (2003). A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 170: 1524-1530.
43. Levine JD, Taiwo YO (1989). Involvement of the mu-opiate receptor in peripheral analgesia. Neuroscience 32: 571-575.
44. Li Q, Verma IM (2002). NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725-734.
45. Lin R, Liu J, Peng N, Yang G, Gan W, Wang W (2005). Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells. Biol Pharm Bull 28: 1630-1634.
46. Lorenzetti BB, Veiga FH, Canetti CA, Poole S, Cunha FQ, Ferreira SH (2002). Cytokine-induced neutrophil chemoattractant 1 (CINC-1) mediates the sympathetic component of inflammatory mechanical hypersensitivitiy in rats. Eur Cytokine Network 13: 456-461.
47. MacMahon S, Sharpe N, Gamble G, Hart H, Scott J, Simes J et al. (1998). Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. Circulation 97: 1784-1790.
48. Maron DJ, Fazio S, Linton MF (2000). Current perspectives on statins. Circulation 101: 207-213.
49. Massy ZA, Keane WF, Kasiske BL (1996). Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? Lancet 347: 102-103.
50. Millan MJ (1999). The induction of pain: an integrative review. Prog Neurobiol 57: 1-164.
51. Moser R, Schleiffenbaum B, Groscurth P, Fehr J (1989). Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 83: 444-455.
52. Muniyappa R, Xu R, Ram JL, Sowers JR (2000). Inhibition of Rho protein stimulates iNOS expression in rat vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 278: H1762-H1768.
53. Nakamura M, Ferreira SH (1987). A peripheral sympathetic component in inflammatory hyperalgesia. Eur J Pharmacol 135: 145-153.
54. Parada CA, Vivancos GG, Tambeli CH, de Queiroz Cunha F, Ferreira SH (2003). Activation of presynaptic NMDA receptors coupled to NaV1.8-resistant sodium channel C-fibers causes retrograde mechanical nociceptor sensitization. Proc Natl Acad Sci USA 100: 2923-2928.
55. Planavila A, Laguna JC, Vazquez-Carrera M (2005). Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim Biophys Acta 1687: 76-83.
56. Prasad R, Giri S, Nath N, Singh I, Singh AK (2005). Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction. J Neurochem 94: 204-214.
57. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S et al. (1998). Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839-844.
58. Rosenson RS (1999). Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1: 225-232.
59. + channel pathway. Proc Natl Acad Sci USA 101: 3680-3685.
60. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ (1995). Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115: 1265-1275.
61. Solheim S, Seljeflot I, Arnesen H, Eritsland J, Eikvar L (2001). Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atherosclerosis 157: 411-415.
62. Sparks DL, Connor DJ, Browne PJ, Lopez JE, Sabbagh MN (2002). HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier. J Nutr Health Aging 6: 324-331.
63. Stein C, Schafer M, Machelska H (2003). Attacking pain at its source: new perspectives on opioids. Nat Med 9: 1003-1008.
64. Taiwo YO, Bjerknes LK, Goetzl EJ, Levine JD (1989). Mediation of primary afferent peripheral hyperalgesia by the cAMP second messenger system. Neuroscience 32: 577-580.
65. Tonussi CR, Ferreira SH (1994). Mechanism of diclofenac analgesia: direct blockade of inflammatory sensitization. Eur J Pharmacol 251: 173-179.
66. Topol EJ (2004). Intensive statin therapy - a sea change in cardiovascular prevention. N Engl J Med 350: 1562-1564.
67. Vaughan CJ, Murphy MB, Buckley BM (1996). Statins do more than just lower cholesterol. Lancet 348: 1079-1082.
68. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M (2000). Improvement of nitric oxide-dependent vasodilatation by HMGCoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20: 61-69.
69. Wallace JL, Morris GP, Beck PL, Williamson TE, Gingras GR (1988). Effects of sucralfate on gastric prostaglandin and leukotriene synthesis: relationship to protective actions. Can J Physiol Pharmacol 66: 666-670.
70. Weitz-Schmidt G (2002). Statins as anti-inflammatory agents. Trends Pharmacol Sci 23: 482-486.
71. Weitz-Schmidt G, Welzenbach K, Brinkmann V, Kamata T, Kallen J, Bruns C et al. (2001). Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 7: 687-692.
72. Wu KK (2005). Control of cyclooxygenase-2 transcriptional activation by pro-inflammatory mediators. Prostaglandins Leukot Essent Fatty Acids 72: 89-93.
73. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM et al. (2002). The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.